Humoral immunity to HIV-1: Kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point

Blood

Volumn 104, Issue 6, 2004, Pages 1784-1792

  Trkola, Alexandra ^a   Kuster, Herbert ^b   Leemann, Christine ^b   Oxenius, Annette ^b   Fagard, Catherine ^b   Furrer, Hansjakob ^b   Battegay, Manuel ^b   Vernazza, Pietro ^b   Bernasconi, Enos ^b   Weber, Rainer ^b   Hirschel, Bernard ^b   Bonhoeffer, Sebastian ^b   Günthard, Huldrych F ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE SYSTEM; INFECTION; KINETICS; MALE; PRIORITY JOURNAL; VACCINATION; VIREMIA; VIRUS INHIBITION;

EID: 4344709657     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0251     Document Type: Article

References (52)

1. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat Med. 2003;9:874-880.
2. Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol. 2002;20:73-99.
3. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol. 2002;2:239-250.
4. Fagard C, Oxenius A, Günthard H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med. 2003;163:1220-1226.
5. Oxenius A, McLean AR, Fischer M, et al. Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Viral. 2002;76:10169-10176.
6. Oxenius A, Price DA, Dawson SJ, et al. Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pre-treatment plasma virus load. AIDS. 2002;16:2317-2322.
7. Oxenius A, Price DA, Günthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A. 2002;99:13747-13752.
8. Fischer M, Hafner R, Schneider C, et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS. 2003;17:195-199.
9. Binley JM, Klasse PJ, Cao Y, et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Viral. 1997;71:2799-2809.
10. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretraviral therapy. J Clin Invest. 1999;104:R13-R18.
11. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol. 1999;73:8966-8974.
12. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295.
13. Trkola A, Kuster H, Leemann C, et al. Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Viral. 2003;77:13146-13155.
14. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417:95-98.
15. Lange CG, Lederman MM. Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J Antimicrob Chemother. 2003;51:1-4.
16. Gandhi RT, Walker BD. Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection. Curr Opin Immunol. 2002;14:487-494.
17. Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol. 2001;13:483-488.
18. Ngo-Giang-Huong N, Candotti D, Goubar A, et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses. 2001;17:1435-1446.
19. Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol. 2001;75:10200-10207.
20. Dybul M. Structured treatment interruption: approaches and risks. Curr Infect Dis Rep. 2002;4:175-180.
21. Forster SM, Osborne LM, Cheingsong-Popov R, et al. Decline of anti-p24 antibody precedes anti-genaemia as correlate of prognosis in HIV-1 infection. AIDS. 1987;1:235-240.
22. Weber JN, Clapham PR, Weiss RA, et al. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet. 1987;1:119-122.
23. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ. 1991;302:23-26.
24. Henrard DR, Daar E, Farzadegan H, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:305-310.
25. Loomis-Price LD, Cox JH, et al. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis. 1998;178:1306-1316.
26. Asjo B, Stavang H, Sorensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses. 2002;18:1357-1365.
27. Benson EM, Clarkson J, Law M, et al. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses. 1999;15:105-113.
28. Jin X, Ramanathan M Jr, Barsoum S, et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Viral. 2002;76:2206-2216.
29. Kelleher AD, Roggensack M, Jaramillo AB, et al. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators. AIDS. 1998;12:175-182.
30. Smith D, Gow I, Colebunders R, et al. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med. 2001;2:272-275.
31. Klein MR, Veenstra J, Holwerda AM, et al. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses. 1997;13:393-399.
32. Lindenburg CE, Stolte I, Langendam MW, et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine. 2002;20:2343-2347.
33. Peters BS, Cheingsong-Popov R, Callow D, et al. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J Infect. 1997;35:231-235.
34. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. J Acquir Immune Defic Syndr Hum Retroviral. 1995;10(suppl 2):S74-S82.
35. Veenstra J, Williams IG, Colebunders R, et al. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis. 1996;174:862-866.
36. Zwart G, van der Hoek L, Valk M, et al. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology. 1994;201:285-293.
37. Chien PC Jr, Cohen S, Kleeberger C, et al. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. J Infect Dis. 2002;186:205-213.
38. Hogervorst E, Jurriaans S, de Wolf F, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis. 1995;171:811-821.
39. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med. 1995;182:185-196.
40. Robinson WE Jr, Montefiori DC, Mitchell WM, et al. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A. 1989;86:4710-4714.
41. Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS. 1999;13:3137-3162.
42. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144-4149.
43. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-312.
44. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995;332:201-208.
45. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis. 1997;176:924-932.
46. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis. 1996;173:60-67.
47. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS. 1998;12:1591-1600.
48. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;6:200-206.
49. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207-210.
50. Montefiori DC, Evans TG. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses. 1999;15:689-698.
51. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys [see comments]. Nat Med. 1999;5:204-210.
52. Hebeis BJ, Klenovsek K, Rohwer P, et al. Activation of virus-specific memory B cells in the absence of T cell help. J Exp Med. 2004;199:593-602.